{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT00992901",
            "orgStudyIdInfo": {
                "id": "18-070H"
            },
            "secondaryIdInfos": [
                {
                    "id": "DK083554",
                    "type": "OTHER_GRANT",
                    "domain": "NIDDK"
                }
            ],
            "organization": {
                "fullName": "The University of Texas Health Science Center at San Antonio",
                "class": "OTHER"
            },
            "briefTitle": "Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery",
            "officialTitle": "Hormonal and Neural Control of Insulin Secretion Following Gastric Bypass Surgery",
            "therapeuticArea": [
                "Other"
            ],
            "study": "role-of-neural-and-hormonal-regulation-factors-on-insulin-secretion-after-gastric-bypass-surgery"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-08",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2009-10"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-08",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-08",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2009-10-07",
            "studyFirstSubmitQcDate": "2009-10-08",
            "studyFirstPostDateStruct": {
                "date": "2009-10-09",
                "type": "ESTIMATED"
            },
            "lastUpdateSubmitDate": "2023-08-21",
            "lastUpdatePostDateStruct": {
                "date": "2023-08-22",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "The University of Texas Health Science Center at San Antonio",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true
        },
        "descriptionModule": {
            "briefSummary": "RYGB (roux-en-y gastric bypass) has been reported to reverse type 2 diabetes (T2DM) immediately after surgery before any significant weight loss. In addition, a growing number of patients have been recognized with life-threatening hyperinsulinemic hypoglycemia several years following their surgery. While the mechanisms by which RYGB improves glucose metabolism or alters islet cell function in patients after RYGB are not understood, recent studies suggest that increased secretion of GI hormones, primarily glucagon-like peptide 1 (GLP-1), as well as alteration in neural activity may contribute to enhanced insulin secretion in general, and to a greater extent in patients with hypoglycemia. The proposed research is designed to address the role of RYGB on insulin secretion by evaluating the contribution of stimulatory factors (neural and GI hormone) on islet cell function and the islet cell responsiveness to the physiologic stimulatory factors, in RYGB patients with and without hypoglycemia and non-operated controls.",
            "detailedDescription": "RYGB (roux-en-y gastric bypass) has been reported to reverse type 2 diabetes (T2DM) immediately after surgery before any significant weight loss. In addition, a growing number of patients have been recognized with life-threatening hyperinsulinemic hypoglycemia several years following their surgery. While the mechanisms by which RYGB improves glucose metabolism or alters islet cell function in patients after RYGB are not understood, recent studies suggest that increased secretion of GI hormones, primarily glucagon-like peptide 1 (GLP-1), as well as alteration in neural activity may contribute to enhanced insulin secretion in general, and to a greater extent in patients with hypoglycemia. The proposed research is designed to address the role of RYGB on insulin secretion by evaluating the contribution of stimulatory factors (neural and GI hormone) on islet cell function and the islet cell responsiveness to the physiologic stimulatory factors, in RYGB patients with and without hypoglycemia and non-operated controls"
        },
        "conditionsModule": {
            "conditions": [
                "Post Bariatricsurgery",
                "Hypoglycemia"
            ],
            "keywords": [
                "gastric bypass surgery",
                "glucose tolerance",
                "Insulin response to meal ingestion",
                "Gut hormone and neural response to meal ingestion"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "EARLY_PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "CROSSOVER",
                "primaryPurpose": "OTHER",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 160,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Exendin-(9-39)",
                    "type": "EXPERIMENTAL",
                    "description": "To evaluate the role of GLP-1 signaling in glucose tolerance and insulin secretion",
                    "interventionNames": [
                        "Drug: Exendin-(9-39)"
                    ]
                },
                {
                    "label": "atropine",
                    "type": "EXPERIMENTAL",
                    "description": "To evaluate the effect of neural activation on insulin secretion and glucose metabolism",
                    "interventionNames": [
                        "Drug: Atropine"
                    ]
                },
                {
                    "label": "GLP-1 and GIP",
                    "type": "EXPERIMENTAL",
                    "description": "to evaluate the beta-cell sensitivity to different doses of exogenous gut hormones",
                    "interventionNames": [
                        "Drug: GLP-1 and GIP"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Exendin-(9-39)",
                    "description": "A physiological study to evaluate the role of GLP-1 signaling in glucose tolerance and insulin secretion",
                    "armGroupLabels": [
                        "Exendin-(9-39)"
                    ],
                    "otherNames": [
                        "No other name for Exendin-(9-39)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Atropine",
                    "description": "A physiological study to evaluate the effect of neural activation on insulin secretion and glucose metabolism",
                    "armGroupLabels": [
                        "atropine"
                    ],
                    "otherNames": [
                        "Atropine sulfate"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "GLP-1 and GIP",
                    "description": "A physiological study to evaluate the beta-cell sensitivity to different doses of exogenous gut hormones",
                    "armGroupLabels": [
                        "GLP-1 and GIP"
                    ],
                    "otherNames": [
                        "No other names for GLP-1 and GIP."
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Gut hormones and neural signaling contribution to insulin secretion rate and glucose tolerance",
                    "timeFrame": "Each study of the protocol is conducted up to seven hours with data collected at intervals specific to the individual study procedure."
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Hypoglycemic RYGB patients with documented blood glucose level \\<50 mg/dl\n* Asymptomatic individuals with bariatric surgery\n* Healthy non-surgical patients with no personal history of diabetes\n* Subjects must physically be able to come to our clinical research center at Cedars-Sinai Medical Center\n\nExclusion Criteria:\n\n* Active heart, lung, liver, gastrointestinal or kidney disease; unable to give informed consent; pregnancy; uncontrolled high blood pressure or high cholesterol; significant anemia (hemoglobin \\<11g/dL); prisoners or institutionalized individuals; type 2 diabetes melitis; development of any serious medical or psychiatric illness during recruitment or studies;\n* RYGB patients will also be disqualified if they have gastric outlet obstruction or severe diarrhea\n* Healthy non-surgical patients with personal history of diabetes\n\nFor administration of atropine, the following exclusions also apply:\n\n* History of glaucoma\n* Uncontrolled hypertension (any subjects with BP\\>140/90 and history of dyslipidemia\n* Taking any medication that might interact with atropine and cannot be stopped will be excluded from the study)\n* Myasthenia gravis\n* Brain pathology\n* Enlarged prostate in men",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "65 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Marzieh Salehi, MD MS",
                    "role": "CONTACT",
                    "phone": "210-567-6691",
                    "email": "salehi@uthscsa.edu"
                },
                {
                    "name": "Andrea Hansis-Diarte",
                    "role": "CONTACT",
                    "phone": "210-567-6691",
                    "email": "hansisdiarte@uthscsa.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Marzieh Salehi, MD, MS",
                    "affiliation": "Marzieh Salehi",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Texas Diabetes Institute - University Health System",
                    "status": "RECRUITING",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78207",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Andrea Hansis-Diarte, MPh",
                            "role": "CONTACT",
                            "phone": "210-567-6691",
                            "email": "hansisdiarte@uthscsa.edu"
                        },
                        {
                            "name": "Marzieh Salehi, MD, MS",
                            "role": "CONTACT",
                            "phone": "210-567-6691",
                            "email": "salehi@uthscsa.edu"
                        },
                        {
                            "name": "Marzieh Salehi",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                },
                {
                    "facility": "South Texas Veterans Health Care System",
                    "status": "RECRUITING",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78229",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Marzieh Salehi",
                            "role": "CONTACT",
                            "phone": "210-567-6691",
                            "email": "salehi@uthscsa.edu"
                        },
                        {
                            "name": "Andrea Hansis-Diarte",
                            "role": "CONTACT",
                            "phone": "210-567-6691",
                            "email": "hansisdiarte@uthscsa.edu"
                        },
                        {
                            "name": "Marzieh Salehi, MD, MS",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000007003",
                    "term": "Hypoglycemia"
                }
            ],
            "ancestors": [
                {
                    "id": "D000044882",
                    "term": "Glucose Metabolism Disorders"
                },
                {
                    "id": "D000008659",
                    "term": "Metabolic Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10053",
                    "name": "Hypoglycemia",
                    "asFound": "Hypoglycemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11639",
                    "name": "Metabolic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M25403",
                    "name": "Glucose Metabolism Disorders",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000001285",
                    "term": "Atropine"
                },
                {
                    "id": "D000052216",
                    "term": "Glucagon-Like Peptide 1"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000759",
                    "term": "Adjuvants, Anesthesia"
                },
                {
                    "id": "D000000889",
                    "term": "Anti-Arrhythmia Agents"
                },
                {
                    "id": "D000001993",
                    "term": "Bronchodilator Agents"
                },
                {
                    "id": "D000001337",
                    "term": "Autonomic Agents"
                },
                {
                    "id": "D000018373",
                    "term": "Peripheral Nervous System Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018927",
                    "term": "Anti-Asthmatic Agents"
                },
                {
                    "id": "D000019141",
                    "term": "Respiratory System Agents"
                },
                {
                    "id": "D000009184",
                    "term": "Mydriatics"
                },
                {
                    "id": "D000010276",
                    "term": "Parasympatholytics"
                },
                {
                    "id": "D000018727",
                    "term": "Muscarinic Antagonists"
                },
                {
                    "id": "D000018680",
                    "term": "Cholinergic Antagonists"
                },
                {
                    "id": "D000018678",
                    "term": "Cholinergic Agents"
                },
                {
                    "id": "D000018377",
                    "term": "Neurotransmitter Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000054795",
                    "term": "Incretins"
                },
                {
                    "id": "D000006728",
                    "term": "Hormones"
                },
                {
                    "id": "D000006730",
                    "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M9789",
                    "name": "Hormones",
                    "relevance": "LOW"
                },
                {
                    "id": "M26997",
                    "name": "Glucagon-Like Peptide 1",
                    "asFound": "Extra",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10365",
                    "name": "Insulin",
                    "relevance": "LOW"
                },
                {
                    "id": "M173166",
                    "name": "Insulin, Globin Zinc",
                    "relevance": "LOW"
                },
                {
                    "id": "M4590",
                    "name": "Atropine",
                    "asFound": "Days per",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9043",
                    "name": "Glucagon",
                    "relevance": "LOW"
                },
                {
                    "id": "M4107",
                    "name": "Anesthetics",
                    "relevance": "LOW"
                },
                {
                    "id": "M4089",
                    "name": "Adjuvants, Anesthesia",
                    "relevance": "LOW"
                },
                {
                    "id": "M4213",
                    "name": "Anti-Arrhythmia Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M5269",
                    "name": "Bronchodilator Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20963",
                    "name": "Anti-Asthmatic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M21137",
                    "name": "Respiratory System Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M12139",
                    "name": "Mydriatics",
                    "relevance": "LOW"
                },
                {
                    "id": "M13189",
                    "name": "Parasympatholytics",
                    "relevance": "LOW"
                },
                {
                    "id": "M20801",
                    "name": "Muscarinic Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M20758",
                    "name": "Cholinergic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20760",
                    "name": "Cholinergic Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M20504",
                    "name": "Neurotransmitter Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M27905",
                    "name": "Incretins",
                    "relevance": "LOW"
                },
                {
                    "id": "M9788",
                    "name": "Hormone Antagonists",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Hypo",
                    "name": "Hypoglycemic Agents"
                },
                {
                    "abbrev": "AnArAg",
                    "name": "Anti-Arrhythmia Agents"
                },
                {
                    "abbrev": "AdjAn",
                    "name": "Adjuvants, Anesthesia"
                },
                {
                    "abbrev": "Resp",
                    "name": "Respiratory System Agents"
                },
                {
                    "abbrev": "Gast",
                    "name": "Gastrointestinal Agents"
                },
                {
                    "abbrev": "CNSDep",
                    "name": "Central Nervous System Depressants"
                }
            ]
        }
    },
    "hasResults": false
}